TP53 and cancer: The combination of PARP and WEE1 inhibitors abrogates G2 arrest and induces mitotic catastrophe, yielding promising results in small cell lung cancer (Lallo et al. 2018), KRAS mutated nonsmall cell lung cancers (Parsels et al. 2018), gastric cancer (Lin et al. 2018), and TP53 mutated cancer (Meng et al. 2018).